Identifying Cancer-Specific Proteins Using Next-Gen Protein Sequencing

This case study details the integration of Quantum-Si’s Platinum technology in the research workflow at Sanavia Oncology, focusing on the identification of cancer-specific proteins. The document outlines the challenges faced in oncology, particularly the investigation of non-response to cancer therapies using traditional mass spectrometry, which is limited by long turnaround times and difficulties in detecting subtle protein variations. The case study presents the innovative approach of using next-generation protein sequencing (NGPS) alongside mass spectrometry to enhance target validation. It describes how the Platinum instrument allows for parallel analyses, providing orthogonal data that increases confidence in findings. The study emphasizes the advantages of NGPS, including its ability to detect subtle variations at single-molecule resolution, thereby accelerating the discovery of novel cancer targets and potential antibody drug candidates. The document also highlights the positive experience of Sanavia with the Platinum instrument, noting its potential for future advancements in cancer research.